Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Interleukin 5 (IL-5) is a key cytokine in the regulation of eosinophilia and eosinophil activation in humans. Monoclonal antibodies to anti-IL-5 have become available for use in clinical studies in humans. This article discusses the rationale for the use of anti-IL-5 therapy in asthma and hypereosinophilic syndrome and summarizes the available clinical data on the use of anti-IL-5 to treat these disorders.
Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Guy Scadding Building, Dovehouse Street, London, SW3 6LY UK. a.b.kay@imperial.ac.uk
A Barry
AB
Kay
Amy D
AD
Klion
D001249:Asthma / Q000188:drug therapy* / Q000209:etiology; D004804:Eosinophils / Q000502:physiology; D016326:Extracellular Matrix Proteins / Q000235:genetics; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D015848:Interleukin-5 / Q000037:antagonists & inhibitors* / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D016212:Transforming Growth Factor beta / Q000235:genetics; D053773:Transforming Growth Factor beta1
D016326:Extracellular Matrix Proteins; D015848:Interleukin-5; D012333:RNA, Messenger; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1